A Novel DNA Vaccine for the Treatment of Malignancies Expressing Immature Laminin Receptor Protein
Description of Invention:
This invention describes a new potent chemoattractant-based DNA vaccine to evoke therapeutic anti-tumor responses against tumors. The vaccine targets the antigen presenting cells (APCs) to efficiently present an antigen to MHC class I and class II molecules to induce tumor specific CD4 and CD8 T cell responses.
The antigen tested is a highly conserved oncofetal antigen named immature laminin receptor protein (OFA-iLRP) that is preferentially expressed in malignant tissues. The vaccine construct consists of novel fusion proteins with enhanced binding affinities to augment antigen processing and antitumor responses.
Applications and Modality:
In vivo laboratory data shows that OFA-iLRP can be used as a potential immunotherapeutic antigen for the treatment of several malignancies including lymphoma, breast, lung, and ovarian.
The vaccine construct is a novel fusion protein designed to enhance immunogenicity of OFA-iLRP via delivering it to chemokine receptors expressed on antigen presenting cells.
The vaccine formulation will be most effective if used for treatment of cancer patients with minimal residual disease to protect from the disease relapse.
The vaccine potentially is effective as a preventive measure for people with cancer predisposition by eliciting long term anti-OFA-iLRP humoral and cellular memory.
Very simple and less invasive vaccine that can be easily delivered to the skin, muscle or other tissues.
Market:
Previous attempts to produce a vaccine construct with OFA-iLRP antigen have been laborious, expensive and non-reproducible showing no definitive demonstrations on the efficacy use of OFA-iLRP as a cancer vaccine. This simple chemoattractant based DNA vaccine is effective, potential cancer therapy with extensive in vivo data. It can be a valuable addition to the fast growing cancer vaccine market.
Development Status:
The technology is currently in the pre-clinical stage of development and planed for clinical tests in patients with NSCLC (tentative start date 2008).
Patent Status:
DHHS Reference No. E-271-2006/0 --
U.S. Provisional Application No. 60/841,927 filed 01 Sep 2006, entitled "Methods and Compositions for the Treatment and Prevention of Cancer"
U.S. Patent Application No. 11/899,165 filed 03 Sep 2007
Relevant Publication:
A manuscript directly related to this technology will be available as soon as it is accepted for publication.
A Biragyn et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol. 1999 Mar;17(3):253-258. [PubMed abs]
A Biragyn et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001 Dec 1;167(11):6644-6653. [PubMed abs]
Licensing Status:
Available for exclusive and non-exclusive licensing.
Collaborative Research Opportunity:
The National Institute on Aging, Immunotherapeutics Unit, Laboratory of Immunology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize simple and potent vaccines that target embryonic antigens expressed in tumors. Please contact John D. Hewes, Ph.D. at (301) 435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Cancer
Cancer -Therapeutics-Vaccines Cancer -Therapeutics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
